MedTrace Logo

Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26

NCT04746638 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-11-28

No results posted yet for this study

Summary

The study should evaluate the biological distribution of 99mTc-RM26 in patients with prostate cancer and breast cancer.

The primary objective are:

1. To assess the distribution of 99mTc- RM26 in normal tissues and tumors at different time intervals.
2. To evaluate dosimetry of 99mTc- RM26.
3. To study the safety and tolerability of the drug 99mTc- RM26 after a single injection in a diagnostic dosage.

The secondary objective are:

1\. To compare the obtained 99mTc- RM26 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer and breast cancer patients.

Conditions

Interventions

DIAGNOSTIC_TEST

whole body study and SPECT with 99mTc-RM26

One single intravenous injection of 99mTc-RM26, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • Tomsk National Research Medical Center of the Russian Academy of Sciences

    lead OTHER

Principal Investigators

  • Vladimir I Chernov, MD,PhD · Tomsk NRMC

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-05-19
Completion
2023-06-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746638 on ClinicalTrials.gov